These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 37164926)

  • 41. Antibacterial-associated acute kidney injury among older adults: A post-marketing surveillance study using the FDA adverse events reporting system.
    Chinzowu T; Chyou TY; Nishtala PS
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1190-1198. PubMed ID: 35670078
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022).
    Ren X; Wang H; Deng L; Wang W; Wang Y
    Int Immunopharmacol; 2024 Jul; 136():112301. PubMed ID: 38838553
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
    Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
    Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System.
    Borrelli EP; Lee EY; Descoteaux AM; Kogut SJ; Caffrey AR
    Epilepsia; 2018 Dec; 59(12):2318-2324. PubMed ID: 30395352
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.
    Jiang A; Wei C; Zhu W; Wu F; Wu B
    Ther Adv Drug Saf; 2024; 15():20420986241244585. PubMed ID: 38715707
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.
    Ke C; Chen M; Huang Y; Chen Y; Lin C; Huang P
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):5253-5264. PubMed ID: 38270617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Research on Beers Criteria and STOPP/START Criteria based on the FDA FAERS database.
    Shao Q; Xu Y; Li M; Chu X; Liu W
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1147-1156. PubMed ID: 34170370
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis.
    Chen C; Zhou R; Fu F; Xiao J
    Eur Psychiatry; 2023 Nov; 66(1):e99. PubMed ID: 38031404
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system.
    Xiao Z; Cao J; Wu S; Zhou T; Li C; Duan J; Yang Z; Xu F
    CNS Neurosci Ther; 2024 Jul; 30(7):e14862. PubMed ID: 39009505
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System.
    Barbieri MA; Russo G; Sorbara EE; Cicala G; Franchina T; Santarpia M; Speranza D; Spina E; Silvestris N
    Front Oncol; 2023; 13():1268672. PubMed ID: 38023143
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
    Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
    Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.
    Zhao D; Zhang W; Liu Y; Yan Z
    Front Pharmacol; 2024; 15():1389814. PubMed ID: 38783948
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.
    Altebainawi AF; Alfaraj LA; Alharbi AA; Alkhuraisi FF; Alshammari TM
    Ther Adv Drug Saf; 2023; 14():20420986231154075. PubMed ID: 36875514
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Signal mining of adverse reactions in the antiemetic drug ondansetron during pregnancy: A real-world analysis of the FDA adverse event reporting system (FAERS).
    Chen T; Chen C; Zhou H; Zhang J
    Expert Opin Drug Saf; 2024 Aug; ():1-9. PubMed ID: 39099462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database.
    Xu Y; Yan C; Zhao Y; Li D; Guo M; Cui X
    Cancer Med; 2023 Apr; 12(8):9167-9174. PubMed ID: 36734333
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Zheng Y; Guo X; Chen C; Chi L; Guo Z; Liang J; Wei L; Chen X; Ye X; He J
    Br J Clin Pharmacol; 2023 Feb; 89(2):865-873. PubMed ID: 36106653
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.
    Pan Y; Wang Y; Zheng Y; Chen J; Li J
    Front Pharmacol; 2024; 15():1251961. PubMed ID: 38655177
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
    Ali Z; Ismail M; Khan F; Sajid H
    Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
    [No Abstract]   [Full Text] [Related]  

  • 60. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
    Salem JE; Manouchehri A; Moey M; Lebrun-Vignes B; Bastarache L; Pariente A; Gobert A; Spano JP; Balko JM; Bonaca MP; Roden DM; Johnson DB; Moslehi JJ
    Lancet Oncol; 2018 Dec; 19(12):1579-1589. PubMed ID: 30442497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.